| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
We describe an EBV-driven lytic system (LySED) that can be used to specifically target therapy to EBV-containing tumors. This system takes advantage of the transactivating properties of EBNA-1, a latency protein expressed in all EBV-containing cells, to drive the expression of Zta, a gene sufficient for inducing the EBV lytic cycle. Thus, EBV provides both the target and the executor for mediating tumor-specific cell death, markedly increasing the specificity of the system. Transfection of EBV-positive cell lines with the LySED construct resulted in a switch to lytic cycle and subsequent cell death, even in the presence of an inhibitor of EBV thymidine kinase (acyclovir) without an increase in virion production. In contrast, growth of EBV-negative B-cell lines was not affected.
1 To whom requests for reprints should be addressed, at Lymphoma Biology Section, Pediatric Branch, National Cancer Institute, NIH, Building 10, Room 13N240, 10 Center Drive, MSC 1928, Bethesda, MD 20892-1928. Phone: (301) 496-2321; Fax: (301) 480-5648.
Received 11/27/95. Accepted 1/17/96.
This article has been cited by other articles:
|
|
 |
|
  M. C. Chia, A. Leung, T. Krushel, N. M. Alajez, K. W. Lo, P. Busson, H. J. Klamut, C. Bastianutto, and F.-F. Liu Nuclear Factor-Y and Epstein Barr Virus in Nasopharyngeal Cancer Clin. Cancer Res., February 15, 2008; 14(4): 984 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gershburg and J. S. Pagano Epstein-Barr virus infections: prospects for treatment J. Antimicrob. Chemother., August 1, 2005; 56(2): 277 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-h. Feng, G. Hong, H.-J. Delecluse, and S. C. Kenney Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas J. Virol., February 15, 2004; 78(4): 1893 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-h. Feng, B. Israel, N. Raab-Traub, P. Busson, and S. C. Kenney Chemotherapy Induces Lytic EBV Replication and Confers Ganciclovir Susceptibility to EBV-positive Epithelial Cell Tumors Cancer Res., March 1, 2002; 62(6): 1920 - 1926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Westphal, W. Blackstock, W. Feng, B. Israel, and S. C. Kenney Activation of Lytic Epstein-Barr Virus (EBV) Infection by Radiation and Sodium Butyrate in Vitro and in Vivo: A Potential Method for Treating EBV-positive Malignancies Cancer Res., October 1, 2000; 60(20): 5781 - 5788. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Charo, A.-M. T. Ciupitu, A. Le Chevalier de Preville, P. Trivedi, G. Klein, J. Hinkula, and R. Kiessling A Long-Term Memory Obtained by Genetic Immunization Results in Full Protection from a Mammary Adenocarcinoma Expressing an EBV Gene J. Immunol., December 1, 1999; 163(11): 5913 - 5919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rodriguez, M. Armstrong, D. Dwyer, and E. Flemington Genetic Dissection of Cell Growth Arrest Functions Mediated by the Epstein-Barr Virus Lytic Gene Product, Zta J. Virol., November 1, 1999; 73(11): 9029 - 9038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Magrath and K. Bhatia Breast Cancer: a New Epstein-Barr Virus-Associated Disease? J Natl Cancer Inst, August 18, 1999; 91(16): 1349 - 1350. [Full Text] [PDF]
|
|
|
|
|
|
E.-M. Westphal, A. Mauser, J. Swenson, M. G. Davis, C. L. Talarico, and S. C. Kenney Induction of Lytic Epstein-Barr Virus (EBV) Infection in EBV-associated Malignancies Using Adenovirus Vectors in Vitro and in Vivo Cancer Res., April 1, 1999; 59(7): 1485 - 1491. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
